Intercept Pharmaceuticals (NAS:ICPT) EV-to-EBIT

: -2.08 (As of Today)

View and export this data going back to 2012. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Intercept Pharmaceuticals's Enterprise Value is $327.2 Mil. Intercept Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 was $-157.6 Mil. Therefore, Intercept Pharmaceuticals's EV-to-EBIT for today is -2.08.

The historical rank and industry rank for Intercept Pharmaceuticals's EV-to-EBIT or its related term are showing as below:

ICPT' s EV-to-EBIT Range Over the Past 10 Years
Min: -553.73 Med: -9.06 Max: -1.45
Current: -2.08

During the past 13 years, the highest EV-to-EBIT of Intercept Pharmaceuticals was -1.45. The lowest was -553.73. And the median was -9.06.

ICPT's EV-to-EBIT is ranked worse than
100% of 459 companies
in the Biotechnology industry
Industry Median: 6.23 vs ICPT: -2.08

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Intercept Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2023 was $459.3 Mil. Intercept Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 was $-157.6 Mil. Intercept Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2023 was -34.31%.

Intercept Pharmaceuticals EV-to-EBIT Historical Data

The historical data trend for Intercept Pharmaceuticals's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intercept Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EV-to-EBIT

-10.50

-12.98

-4.04

-7.16

-2.31

Intercept Pharmaceuticals Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
EV-to-EBIT																-11.08	-9.68	-2.46	-2.31	-2.91

Competitive Comparison

For the Biotechnology subindustry, Intercept Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

Intercept Pharmaceuticals EV-to-EBIT Distribution

For the Biotechnology industry and Healthcare sector, Intercept Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Intercept Pharmaceuticals's EV-to-EBIT falls in comparison to its industry or sector. The grey bar indicates the EV-to-EBIT's extreme value range as defined by GuruFocus.

Intercept Pharmaceuticals EV-to-EBIT Calculation

Intercept Pharmaceuticals's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	327.154	/	-157.577
	=	-2.08

Intercept Pharmaceuticals's current Enterprise Value is $327.2 Mil.
Intercept Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-157.6 Mil.

Intercept Pharmaceuticals (NAS:ICPT) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Intercept Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2023 )	=	EBIT	/	Enterprise Value (Q: Mar. 2023 )
	=	-157.577	/	459.302753
	=	-34.31 %

Intercept Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2023 was $459.3 Mil.
Intercept Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-157.6 Mil.

Intercept Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Intercept Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Intercept Pharmaceuticals (NAS:ICPT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intercept Pharmaceuticals Inc (NAS:ICPT) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

I4P:Germany

Address

10 Hudson Yards, 37th Floor, New York, NY, USA, 10001

Website

https://www.interceptpharma.com

Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.

Executives

Andrew Saik	officer: EVP & Chief Financial Officer	640 LEE ROAD, CHESTERBROOK PA 19087
M Michelle Berrey	officer: President, R&D and CMO	303A COLLEGE ROAD EAST, PRINCETON NJ 08450
Dagmar Rosa-bjorkeson	director	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Rocco Venezia	officer: Chief Accounting Officer	C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FLOOR, NEW YORK NY 10001
Lisa Defrancesco	officer: SVP, IR & Corp. Affairs	C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, FLOOR 37, NEW YORK NY 10001
Linda M Richardson	officer: EVP & Chief Commercial Officer	2505 MERIDIAN PKWY, SUITE 340, C/O CHIMERIX, INC., DURHAM NC 27713
Jared Freedberg	officer: General Counsel and Secretary	300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Bryan Ball	officer: Chief Quality Officer	300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Paolo Fundaro	director, 10 percent owner	C/O GENEXTRA S.P.A.,, VIA G. DE GRASSI, 11, MILAN L6 20123
Keith Michael Gottesdiener	director	900 FIFTH AVENUE, #8C, NEW YORK NY 10021
Luca Benatti	director	C/O INTERCEPT PHARMACEUTICALS, INC., 450 WEST 15TH STREET, SUITE 505, NEW YORK NY 10011
Daniel G Welch	director	4611 UNIVERSITY DR, 4 UNIVERSITY PLACE, DURHAM NC 27707
Daniel Bradbury	director	BIOBRIT, LLC, 2223 AVENIDA DE LA PLAYA, SUITE 108, LA JOLLA CA 92037
Nancy Miller-rich	director	C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FL, NEW YORK NY 10001
Gino Santini	director	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451